Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. (Record no. 1503)

MARC details
000 -LEADER
fixed length control field 03892nam a22004937a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 140821s20142014 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0732-183X
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 24711552
245 ## - TITLE STATEMENT
Title Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.
251 ## - Source
Source Journal of Clinical Oncology. 32(14):1427-36, 2014 May 10.
252 ## - Abbreviated Source
Abbreviated source J Clin Oncol. 32(14):1427-36, 2014 May 10.
253 ## - Journal Name
Journal name Journal of clinical oncology : official journal of the American Society of Clinical Oncology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2014
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2014
266 ## - Date added to catalog
Date added to catalog 2014-08-21
501 ## - WITH NOTE
Local holdings Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008
520 ## - SUMMARY, ETC.
Abstract CONCLUSION: Exemestane given for prevention has limited negative impact on menopause-specific and health-related QOL in healthy postmenopausal women at risk for breast cancer.
520 ## - SUMMARY, ETC.
Abstract PATIENTS AND METHODS: Menopause-specific and health-related QOL were assessed by using the four Menopause-Specific Quality of Life Questionnaire (MENQOL) domains and the eight Medical Outcomes Study Short Form Health Survey (SF-36) scales at baseline, 6 months, and yearly thereafter. MENQOL questionnaire completion was high (88% to 98%) in both groups at each follow-up visit. 20140821 scores for each MENQOL and SF-36 scale, calculated at each assessment time relative to baseline, were compared by using the Wilcoxon rank-sum test. Clinically important worsened QOL was defined as a MENQOL 20140821 score increase of more than 0.5 (of 8) points and an SF-36 20140821 score decrease of more than 5 (of 100) points from baseline.
520 ## - SUMMARY, ETC.
Abstract PURPOSE: Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial, but effects on quality of life (QOL) were not fully described.
520 ## - SUMMARY, ETC.
Abstract RESULTS: Exemestane had small negative effects on women's self-reported vasomotor symptoms, sexual symptoms, and pain, which occurred mainly in the first 6 months to 2 years after random assignment. However, these 140821s represented only a small excess number of women being given exemestane with clinically important worsening of QOL at one time or another; specifically, 8% more in the vasomotor domain and 4% more each in the sexual domain and for pain. No other between-group differences were observed. Overall, slightly more women in the exemestane arm (32%) than in the placebo arm (28%) discontinued assigned treatment.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Androstadienes/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Aromatase Inhibitors/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Breast Neoplasms/pc [Prevention & Control]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Quality of Life
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged, 80 and over
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Postmenopause
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Questionnaires
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Health Research Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Multicenter Study
657 ## - INDEX TERM--FUNCTION
Medline publication type Randomized Controlled Trial
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, Non-U.S. Gov't
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Thayer, Debra W
790 ## - Authors
All authors Ales-Martinez JE, Brundage M, Cheung AM, Chlebowski RT, Cooke AL, Dube P, Ellard SL, Fabian CJ, Gelmon KA, Goss PE, Hendrix S, Hiltz A, Ingle JN, Johnston D, Lickley L, Maunsell E, Pater JL, Pruthi S, Pujol P, Richardson H, Rowland KM, Ruiz A, Sarto GE, Spadafora S, Thayer DW, Tu D, Wactawski-Wende J
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="http://dx.doi.org/10.1200/JCO.2013.51.2483">http://dx.doi.org/10.1200/JCO.2013.51.2483</a>
Public note http://dx.doi.org/10.1200/JCO.2013.51.2483
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 08/21/2014   24711552 24711552 08/21/2014 08/21/2014 Journal Article

Powered by Koha